SREBF1 and metabolic dysfunction-associated steatotic liver disease: The activation of the hepatic A1 adenosine receptor (A1AR) inhibited the maturation of SREBPs by reducing SCAP content and its anchoring in the Golgi apparatus, while prevented the phosphorylation and nuclear translocation of mature SREBPs, particularly SREBP1c and SREBP2 by decreasing adenylate cyclase activity to reduce cAMP levels and lower protein kinase A catalytic subunit (PKAc) activity, eventually, reducing lipid accumulation, and slowing progression of MASLD caused by HFD [10].